RISITANO, ANTONIO MARIA

RISITANO, ANTONIO MARIA  

DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 191 (tempo di esecuzione: 0.032 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Eculizumab treatment modifies the immune profile of PNH patients. 1.1 Articolo in rivista 2012 Alfinito, Fiorella; Ruggiero, Giuseppina; Sica, M.; Udhayachandran, A.; Rubino, Valentina; Pepa, R. D.; Palantucci, A. T.; Annunziatella, M.; Notaro, R.; Risitano, ANTONIO MARIA; Terrazzano, G.
Pathological clonal cytotoxic T cell responses - non random nature of the T cell receptor restriction in large granular lymphocytic leukemia. 1.1 Articolo in rivista 2005 Wlodarski, Mw; O’Keefe, C; Howe, Ec; Loughran J. r., Tp; Risitano, ANTONIO MARIA; Rodriguez, A; Warshawsky, I; Maciejewski, J. P.
In vivo dominant immune responses in aplastic anemia patients: molecular tracking of putatively pathogenic T cells by TCRb-CDR3 sequencing. 1.1 Articolo in rivista 2004 Risitano, ANTONIO MARIA; Maciejewski, Jp; Green, S; Plasilova, M; Zeng, W; Young, N. S.
Preferential suppression of trisomy 8 versus normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodisplastic syndrome. 1.1 Articolo in rivista 2005 Sloand, Em; Mainwaring, L; Fuhrer, M; Ramkissoon, S; Risitano, ANTONIO MARIA; Keyvanafar, K; Lu, J; Basu, A; Barrett, Aj; Young, N. S.
Application of the molecular analsysis of the T –cell receptor repertoire in the study of immune-mediated hematologic disease. 1.1 Articolo in rivista 2002 Plasilova, M; Risitano, ANTONIO MARIA; Maciejewski, J. P.
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria. 1.1 Articolo in rivista 2013 Hillmen, P; Muus, P; Röth, A; Elebute, Mo; Risitano, ANTONIO MARIA; Schrezenmeier, H; Szer, J; Browne, P; Maciejewski, Jp; Schubert, J; Urbano Ispizua, A; de Castro, C; Socié, G; Brodsky, R. A.
A pilot study of the recombinant soluble human tumor necrosis factor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 1.1 Articolo in rivista 2002 Jp, Maciejewski; Risitano, ANTONIO MARIA; L., Wisch; N., Geller; J., Barrett; Ns, Y. o. u. n. g.
Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein (PrPc). 1.1 Articolo in rivista 2002 K., Holada; J., Simak; Risitano, ANTONIO MARIA; J., Maciejewski; Ns, Young; Jg, V. o. s. t. a. l.
Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 1.1 Articolo in rivista 2008 Brodsky, Ra; Young, Ns; Antonioli, E; Risitano, ANTONIO MARIA; Schrezenmeier, H; Schubert, J; Valls, Ag; Coyle, L; de Castro, C; Fu, Cl; Maciejewski, Jp; Bessler, M; Kroon, Ha; Rother, Rp; Hillmen, P.
Valgancyclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. 1.1 Articolo in rivista 2009 Risitano, ANTONIO MARIA; Serio, B; Selleri, C; Rotoli, B.
Rabbit ATG for aplastic anaemia treatment: a backward step? 1.1 Articolo in rivista 2011 European, Blood; Marrow Transplant, Group; Dufour C, Severe Aplastic Anaemia Working P. a. r. t. y.; Bacigalupo, A; Oneto, R; Socie, G; Tichelli, A; Passweg, Jr; Risitano, ANTONIO MARIA; Schrezenmeier, H; Locasciulli, A; Aljurf, M; Marsh, J. C.
Significance of oligoclonal and polyclonal expansion within CD8 and CD4 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by VB CDR3 spectratyping and flow cytometry. 1.1 Articolo in rivista 2002 Risitano, ANTONIO MARIA; H., Kook; W., Zeng; G., Chen; Ns, Young; Jp, M. a. c. i. e. j. e. w. s. k. i.
Aplastic anemia: immunosuppression. Current challenges and future goals in immunosuppression for aplastic anemia. 1.1 Articolo in rivista 2009 Risitano, ANTONIO MARIA
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010 Meeting Report. 1.1 Articolo in rivista 2011 Malcovati, L; de Latour, Rp; Risitano, ANTONIO MARIA
Immune pathophysiology of aplstic anemia. 1.1 Articolo in rivista 2002 Jp, Maciejewski; Risitano, ANTONIO MARIA; H., Kook; W., Zeng; G., Chen; Ns, Y. o. u. n. g.
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. 1.1 Articolo in rivista 2011 Fridkis Hareli, M; Storek, M; Mazsaroff, I; Risitano, ANTONIO MARIA; Lundberg, As; Horvath, Cj; Holers, V. M.
Paroxysmal nocturnal hemoglobinuria and other complement-mediated haematological disorders. Immunobiology. 1.1 Articolo in rivista 2012 Risitano, ANTONIO MARIA
Multi-center experience using total lymphoid irradiation and anti-thymocyte globulin as conditioning for allografting in hematological malignancies. 1.1 Articolo in rivista 2012 Messina, G; Giaccone, L; Festuccia, M; Irrera, G; Scortechini, I; Sorasio, R; Gigli, F; Passera, R; Cavattoni, I; Filippi, Ar; Schianca, Fc; Pini, M; Risitano, ANTONIO MARIA; Selleri, C; Levis, A; Mordini, N; Gallamini, A; Pastano, R; Casini, M; Aglietta, M; Montanari, M; Console, G; Boccadoro, M; Ricardi, U; Bruno, B.
Fas-mediated apoptosis is important in regulating cell replication and death in trysomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. 1.1 Articolo in rivista 2002 Em, Sloand; S., Kim; M., Fuhrer; Risitano, ANTONIO MARIA; R., Nakamura; J., Maciejewski; J., Barrett; Ns, Y. o. u. n. g.
Molecular analysis of T cell receptor clonotypes in LGL- A clonal model for polyclonal responses. 1.1 Articolo in rivista 2004 O’Keefe, C; Plasilova, M; Risitano, ANTONIO MARIA; Rodriguez, A; Hsi, E; Wlodarski, M; Young, Ns; Maciejewski, J. P.